Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Anti-beta 1 integrin humanized antibody, and pharmaceutical composition for treating cancer, comprising same

A technology of integrin and monoclonal antibody, applied in the direction of drug combination, antibody medical ingredients, medical preparations containing active ingredients, etc., can solve problems such as unmet needs

Pending Publication Date: 2021-08-31
SG医疗株式会社
View PDF4 Cites 1 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0008] Therefore, in order to address an unmet need in medicine, namely, to overcome resistance to existing lung cancer therapeutics, there is an emerging need for new drugs that can neutralize pathogens at an early stage, which need to be used in combination with existing drugs

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Anti-beta 1 integrin humanized antibody, and pharmaceutical composition for treating cancer, comprising same
  • Anti-beta 1 integrin humanized antibody, and pharmaceutical composition for treating cancer, comprising same
  • Anti-beta 1 integrin humanized antibody, and pharmaceutical composition for treating cancer, comprising same

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0082] Example 1. Improvement and humanization of cancer cell killing ability of P5

[0083] In order to develop a humanized antibody with improved ability to kill cancer cells compared to P5 (Kim MY et al. J Biomed Res, 2016, 30(3): 217-24), the present inventors conducted the following experiments.

[0084] In order to improve P5, mutations were introduced in 4 FRs of the heavy chain variable region (HFR1, HFR2, HFR3, HFR4) and 4 FRs of the light chain variable region (LFR1, LFR2, LFR3, LFR4) in the following manner.

[0085] 1) Specifically, HFR1 uses IGHV7-4-1*03, HFR2 uses IGHV4-30-4*06, HFR3 uses IGHV1-69-2*01, HFR4 uses the sequence of IGHJ6*01, considering the physicochemical properties of amino acids Similarities and differences, parental antibody was substituted with other amino acids. The amino acids replaced by this method are I20V, T25S, S30T in IGHV7-4-1*03; R40H, H43K in IGHV4-30-4*06; K66R, A67V, F69I in IGHV1-69-2*01 , S75T, N76D, S79Y, Q81E, T83R, S87T; and...

Embodiment 2

[0098] Example 2. Complete antibody conversion and expression / purification of GP5 clones

[0099] The DNA of the GP5 variable region developed in Example 1 was synthesized into a scFv format (Cosmogenetech, Korea), and converted into a full antibody (full IgG) using the PCR method. First, from a pUC vector (Cosmogenetech, Korea) including scFv, V H 、C H and V L 、C KPrimer combinations, sections of the variable and constant regions of the heavy and light chains were obtained by PCR. For the variable region and constant region of the obtained antibody, PCR was performed using the HC and LC primer combinations in Table 2 below to obtain the heavy chain and light chain of GP5. The heavy chain was treated with EcoRI and NotI (New England Biolab, UK) enzymes, and ligated to the same restriction enzyme-treated pCMV vector (Thermo Fisher SCIENTIFIC, USA), which is a vector for animal cell expression. And, the light chain was treated with XbaI (New England Biolab, UK) enzyme, and ...

Embodiment 3

[0105] Example 3. Analysis of the binding ability of GP5 monoclonal antibody to β1 integrin

[0106] The direct ELISA method confirmed the binding ability of the GP5 monoclonal antibody prepared in Example 2 above to β1 integrin. Since the GP5 monoclonal antibody is a humanized antibody, and P5 is a mouse antibody, a peroxidase labeling kit (Peroxidase Labeling)-NH 2 (Dojindo, Japan) labeled each antibody with HRP for direct comparison of binding. In direct ELISA, recombinant human β1 integrin (Sino bio, China) and recombinant mouse β1 integrin (MyBioSource, USA) were diluted at 1 μg / ml in 50 μl PBS, and placed in a 96-well immunoplate (Corning, USA), stored overnight at 4°C for adsorption. After reacting with buffer containing 3% bovine serum albumin (Milipore, USA) for 1 hour at 37°C, dilute to serial concentrations (0.01, 0.03, 0.1, 0.3, 1, 3, 100, 300, 1000 nM) each HRP-labeled antibody was treated at 50 μl per well. After reacting at 37° C. for 2 hours, after the anti...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The present invention relates to a monoclonal antibody or a fragment thereof which recognizes beta 1 integrin as an antigen and thus binds specifically to same. In addition, the present invention relates to a pharmaceutical composition comprising the monoclonal antibody or a fragment thereof for preventing or treating cancer. The monoclonal antibody of the present invention suppresses the proliferation of cancer cells and angiogenesis and effectively induces apoptosis, and thus can be usefully used in preventing or treating cancer.

Description

technical field [0001] The present invention relates to an antibody that specifically binds to β1 integrin that transduces biochemical signals related to the growth, differentiation, invasion and metastasis of cancer cells. In more detail, the antibody of the present invention can inhibit the signal transduction function of β1 integrin. For the diagnosis and treatment of various cancers (eg, non-small cell lung cancer) overexpressing β1 integrin. Background technique [0002] In 2018, there were 18 million cancer cases worldwide and an estimated 9 million deaths. One in five men and one in six women will develop cancer in their lifetime, and one in eight men and one in 11 women will die from it. Globally, the total number of survivors within five years of a cancer diagnosis is estimated at 43.8 million (Press Release N 263, WHO, Internal Agency for Research on Cancer, 12 September 2018). Lung cancer is the three most common cancers with the highest incidence after breast c...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
IPC IPC(8): C07K16/28A61P35/00G01N33/68G01N33/574A61K39/00
CPCA61P35/00G01N33/574G01N33/68G01N2333/7055C07K16/2842A61K2039/505C07K2317/24C07K2317/73C07K2317/622C07K2317/77C07K2317/33A61K39/3955A61K2300/00A61K47/6811G01N33/57423C07K2317/31
Inventor 李志哲朴钟灿闵省远权亨宣
Owner SG医疗株式会社
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com